Toward a treat-to-target approach in the management of juvenile idiopathic arthritis

Clinical and Experimental Rheumatology

Volumn 30, Issue 4 SUPPL.73, 2012, Pages

  Consolaro, A ^a   Negro, G ^a   Lanni, S ^a   Solari, N ^a   Martini, A ^a,b   Ravelli, A ^a,b  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Acceptable symptom state; Inactive disease; Juvenile idiopathic arthritis; Minimal disease activity; Remission; Treat to target

Indexed keywords

BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG;

ARTICLE; CHILD; DISEASE ACTIVITY; HUMAN; JUVENILE ARTHRITIS DISEASE ACTIVITY SCORE; JUVENILE RHEUMATOID ARTHRITIS; PARENT; PATIENT SATISFACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REMISSION; SCORING SYSTEM; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; CHILD; DISEASE MANAGEMENT; DISEASE PROGRESSION; HUMANS; PATIENT CARE PLANNING; REMISSION INDUCTION; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX;

EID: 84870260481     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. RAVELLI A, MARTINI A: Juvenile idiopathic arthritis. Lancet 2007;369:767-78.
2. VIOLA S, FELICI E, MAGNI-MANZONI S et al.: Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis. Arthritis Rheum 2005;52:2092-102.
3. BRUNNER HI, GIANNINI EH: Health-related quality of life in children with rheumatic diseases. Curr Opin Rheumatol 2003;15:602-12.
4. DUFFY CM: Measurement of health status, functional status, and quality of life in children with juvenile idiopathic arthritis: clinical science for the pediatrician. Pediatr Clin North Am 2005;52:359-72.
5. HASHKES PJ, LAXER RN: Medical treatment of juvenile idiopathic arthritis. JAMA 2005;294:1671-84.
6. HAYWARD K, WALLACE CA: Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthritis Res Ther 2009;11:216.
7. RUPERTO N, MARTINI A: Emerging drugs to treat juvenile idiopathic arthritis. Expert Opin Emerg Drugs 2011;16:493-505.
8. WALLACE CA, RUPERTO N, GIANNINI EH: Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004;31:2290-4.
9. WALLACE CA, GIANNINI EH, HUANG B, ITERT L, RUPERTO N: American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res 2011;63:929-36.
10. WALLACE CA, HUANG B, BANDEIRA M, RAVELLI A, GIANNINI EH: Patterns of clinical remission in select categories of juvenile idiopathic arthritis. Arthritis Rheum 2005;52:3554-62.
11. RAVELLI A, MARTINI A: Remission in juvenile idiopathic arthritis. Clin Exp Rheumatol 2006;24(Suppl. 43):S-105-S110.
12. MAGNI-MANZONI S, RUPERTO N, PISTORIO A et al.: Development and validation of a preliminary definition of minimal disease activity in juvenile idiopathic arthritis. Arthritis Rheum 2008;59:1120-7.
13. MARTINI A, LOVELL DJ: Juvenile idiopathic arthritis: state of the art and future perspectives. Ann Rheum Dis 2010;69:1260-3.
14. RUPERTO N, GIANNINI EH, PISTORIO A, BRUNNER HI, MARTINI A, LOVELL DJ: Is it time to move to active comparator trials in juvenile idiopathic arthritis? A review of current study designs. Arthritis Rheum 2010;62:3131-9.
15. MAGNANI A, PISTORIO A, MAGNI-MANZONI S et al.: Achievement of a state of inactive disease at least once in the first 5 years predicts better outcome of patients with polyarticular juvenile idiopathic arthritis. J Rheumatol 2009;36:628-34.
16. GRIGOR C, CAPELL H, STIRLING A et al.: Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9.
17. DE VRIES-BOUWSTRA JK, GOEKOOP-RUITERMEN YP, VAN ZEBEN D, BREEDVELD FC, DIJKMANS BA, HAZES JM: A comparison of clinical and radiological outcomes of four treatment strategies for early rheumatoid arthritis: results of the Best Trial. Ann Rheum Dis 2004;63(Suppl. 1):S58.
18. SMOLEN JS, SOKKA T, PINCUS T, BREEDVELD FC: A proposed treatment algorithm for rheumatoid arthritis: aggressive therapy, methotrexate, and quantitative measures. Clin Exp Rheumatol 2003;21(Suppl. 31):S209-10.
19. BARTOLI M, TARÒ M, MAGNI-MANZONI S et al.: The magnitude of early response to methotrexate therapy predicts the long-term outcome of patients with juvenile idiopathic arthritis. Ann Rheum Dis 2008;67:370-4.
20. ALBERS HM, BRINKMAN D M C, KAMPHUIS S S M et al.: Clinical course and prognostic value of disease activity in the first two years in different subtypes of juvenile idiopathic arthritis. Arthritis Care Res 2010;62:204-12.
21. RAVELLI A, MARTINI A: Early predictors of outcome in juvenile idiopathic arthritis. Clin Exp Rheumatol 2003;21(Suppl. 31):S89-93.
22. WALLACE CA, GIANNINI EH, SPALDING SJ et al.: Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum 2012;64:2012-21.
23. SOKKA T, PINCUS T: Rheumatoid arthritis: strategy more important than agent. Lancet 2009;374:430-2.
24. SMOLEN JS, LANDEWE R, BREEDVELD FC et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
25. SMOLEN JS, ALETAHA D, BLIJLSMA J W J et al.: Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
26. DAVIES K, CLEARY G, FOSTER H, HUTCHINSON E, BAILDAM E: BSPAR Standards of Care for children and young people with juvenile idiopathic arthritis. Rheumatology 2010;49:1406-8.
27. BEUKELMAN T, PATKAR NM, SAAG KG et al.: 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 2011;63:465-82.
28. WALLACE CA: Developing standards of care for patients with juvenile idiopathic arthritis. Rheumatology 2010;49:1213-4.
29. BERESFORD MW, CLEARY AG, FOSTER HE, HUTCHINSON E, BAILDAM EM, DAVIES K: Comment on: Developing standards of care for patients with juvenile idiopathic arthritis. Rheumatology 2010;49:2227-9.
30. WELLS G, BOERS M, SHEA B et al.: MCID/Low Disease Activity State Workshop: low disease activity state in rheumatoid arthritis. J Rheumatol 2003;30:1110-1.
31. FILOCAMO G, CONSOLARO A, SCHIAPPAPIETRA B et al.: Parent and child acceptable symptom state in juvenile idiopathic arthritis. J Rheumatol 2012;39:856-63.
32. VAN DER HEIJDE D M F M, VAN'T HOF M, VAN RIEL P L C M et al.: Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990;49:916-20.
33. ALETAHA D, NELL VP, STAMM T et al.: Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796-806.
34. CONSOLARO A, RUPERTO N, BAZSO A et al.: Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 2009;61:658-66.
35. NORDAL EB, ZAK M, AALTO K et al.: Validity and predictive ability of the juvenile arthritis disease activity score based on CRP versus ESR in a Nordic population-based setting. Ann Rheum Dis 2012;71:1122-7.
36. CONSOLARO A, BRACCIOLINI G, RUPERTO N et al.: Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis. Defining criteria based on the Juvenile Arthritis Disease Activity Score. Arthritis Rheum 2012;64:2366-74.
37. ALETAHA D, SMOLEN J: The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23:S100-8.
38. WAKEFIELD RJ, D'AGOSTINO MA, NAREDO E et al.: After treat-to-target: can a targeted ultrasound iniziative improve RA outcomes? Ann Rheum Dis 2012;71:799-803.
39. van der HEIJDE D: Remission by imaging in rheumatoid arthritis: should this be the ultimate goal? Ann Rheum Dis 2012;71(Suppl. II):i89-i92.
40. TZARIBACHEV N, FRITZ J, HORGER M: Silent arthritis in JIA children with clinically inactive disease detected by MRI. Ann Rheum Dis 2011;70(Suppl. 3):90.
41. GARDNER-MEDWIN JM, KILLEEN OG, RYDER CA, BRADSHAW K, JOHNSON K: Magnetic resonance imaging identifies features in clinically unaffected knees predicting extension of arthritis in children with monoarthritis. J Rheumatol 2006;33:2337-43.
42. MAGNI-MANZONI S, EPIS O, RAVELLI A et al.: Comparison of clinical versus ultrasound-determined synovitis in juvenile idiophatic arthritis. Arthritis Rheum 2009;61:1497-504.
43. BRETON S, JOUSSE-JOULIN S, CANGEMI C et al.: Comparison of clinical and ultrasonographic evaluations for peripheral synovitis in juvenile idiopathic arthritis. Semin Arthritis Rheum 2011;41:272-8.
44. HASLAM KE, MCCANN LI, WYATT S, WAKEFIELD RJ: The detection of subclinical synovitis by ultrasound in oligoarticular juvenile idiopathic arthritis: a pilot study. Rheumatology 2010;49; 123-7.
45. JANOW GL, PANGHAAL V, TRINH A, BADGER D, LEVIN TL, ILOWITE NT: Detection of active disease in juvenile idiopathic arthritis: sensitivity and specificity of the physical examination vs. ultrasound. J Rheumatol 2011;38:2671-4.
46. REBOLLO-POLO M, KOUJOK K, WEISSER C, JURENCAK R, BRUNS A, ROTH J: Ultrasound findings on patients with juvenile idiophatic arthritis in clinical remission. Arthritis Care Res 2011;63:1013-9.
47. MAGNI-MANZONI S, SCIRÉ CA, RAVELLI A et al.: Ultrasound-detected synovial abnormalities are frequent in clinically inactive juvenile idiopathic arthritis, but do not predict a flare of synovitis. Ann Rheum Dis 2012 Jun. 26 [Epub ahead of print].
48. SCIRE CA, MONTECUCCO C, CODULLO V, EPIS O, TODOERTI M, CAPORALI R: Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical remission: power Doppler signal predicts short-term relapse. Rheumatology 2009;48:1092-7.
49. PELUSO G, MICHELUTTI A, BOSELLO S, GREMESE E, TOLUSSO B, FERRACCIOLI G: Clinical and ultrasonographic remission determines different chance of relapse in early and long standing rheumatoid arthritis. Ann Rheum Dis 2011;70:172-5.
50. SALEEM B, BROWN AK, KEEN H et al.: Should imaging be a component of rheumatoid arthritis remission criteria? A comparison between traditional and modified composite remission scores and imaging assessment. Ann Rhum Dis 2011;70:792-8.
51. MAGNI-MANZONI S, MALATTIA C, LANNI S, RAVELLI A: Advances and challenges in imaging in juvenile idiopathic arthritis. Nat Rev Rheumatol 2012;8:329-36.
52. LANNI S, WOOD M, RAVELLI A et al.: Toward a role of ultrasound in juvenile idiopathic arthritis. Rheumatology (In press).
53. PRINCE FH, TWILT M, TEN CATE R et al.: Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 2009;68:635-41.
54. OTTEN MH, PRINCE FH, ARMBRUST W et al.: Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA 2011;21:2340-7.
55. RUPERTO N, LOVELL DJ, QUARTIER P et al.: Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008;372:383-91.